other material
confidence high
sentiment positive
materiality 0.75
LENZ Therapeutics announces positive Phase 3 data for LNZ100 in China presbyopia trial
LENZ Therapeutics, Inc.
- Primary endpoint met: 74% achieved ≥3-line improvement at 3 hours (p<0.0001 vs vehicle).
- Rapid onset: 69% achieved ≥3-line improvement at 30 minutes; 84% achieved ≥2-line improvement.
- Long duration: 30% maintained ≥3-line improvement at 10 hours; 61% achieved ≥2-line improvement.
- No serious treatment-related adverse events observed; well-tolerated in 300-patient study.
- LNZ100 is aceclidine-based eye drop; NDA already accepted by FDA for U.S. market.